These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19081789)

  • 61. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
    Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
    J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Deglycosylation of HIV-1 AE Gp140 enhances the capacity to elicit neutralizing antibodies against the heterologous HIV-1 clade.
    Zhang C; Wan Y; Shi J; Zhou M; Meng Z; Yuan S; Qiu C; Zhang X; Xu X; Liu C; Xu J
    AIDS Res Hum Retroviruses; 2010 May; 26(5):569-75. PubMed ID: 20455767
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
    Moulard M; Phogat SK; Shu Y; Labrijn AF; Xiao X; Binley JM; Zhang MY; Sidorov IA; Broder CC; Robinson J; Parren PW; Burton DR; Dimitrov DS
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6913-8. PubMed ID: 11997472
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies.
    Deshpande S; Patil S; Kumar R; Shrivastava T; Srikrishnan AK; Murugavel KG; Koff WC; Chakrabarti BK; Bhattacharya J
    Retrovirology; 2016 Jun; 13(1):41. PubMed ID: 27307004
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.
    Gift SK; Leaman DP; Zhang L; Kim AS; Zwick MB
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978711
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.
    He Y; Honnen WJ; Krachmarov CP; Burkhart M; Kayman SC; Corvalan J; Pinter A
    J Immunol; 2002 Jul; 169(1):595-605. PubMed ID: 12077293
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes.
    Das S; Boliar S; Mitra N; Samal S; Bansal M; Koff WC; Chakrabarti BK
    Retrovirology; 2016 Nov; 13(1):81. PubMed ID: 27871328
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
    Moore JP; Ho DD
    J Virol; 1993 Feb; 67(2):863-75. PubMed ID: 7678308
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Proteins mimicking epitope of HIV-1 virus neutralizing antibody induce virus-neutralizing sera in mice.
    Kosztyu P; Kuchar M; Cerny J; Barkocziova L; Maly M; Petrokova H; Czernekova L; Liskova V; Raskova Kafkova L; Knotigova P; Masek J; Turanek J; Maly P; Raska M
    EBioMedicine; 2019 Sep; 47():247-256. PubMed ID: 31544770
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy.
    Marcelino JM; Borrego P; Rocha C; Barroso H; Quintas A; Novo C; Taveira N
    J Virol; 2010 Dec; 84(23):12429-36. PubMed ID: 20844029
    [TBL] [Abstract][Full Text] [Related]  

  • 73. T-cell immune responses against Env from CRF12_BF and subtype B HIV-1 show high clade-specificity that can be overridden by multiclade immunizations.
    Mónaco DC; Rodríguez AM; Pascutti MF; Carobene M; Falivene J; Gómez A; Maeto C; Turk G; Nájera JL; Esteban M; Gherardi MM
    PLoS One; 2011 Feb; 6(2):e17185. PubMed ID: 21364754
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.
    Bontjer I; Melchers M; Eggink D; David K; Moore JP; Berkhout B; Sanders RW
    J Biol Chem; 2010 Nov; 285(47):36456-70. PubMed ID: 20826824
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120.
    Kirchherr JL; Hamilton J; Lu X; Gnanakaran S; Muldoon M; Daniels M; Kasongo W; Chalwe V; Mulenga C; Mwananyanda L; Musonda RM; Yuan X; Montefiori DC; Korber BT; Haynes BF; Gao F
    Virology; 2011 Jan; 409(2):163-74. PubMed ID: 21036380
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The production, characterisation and application of monoclonal antibodies generated by immunisation with HIV-1C clade RGP140 envelope protein.
    Hassall M; Page M; Robinson M; Jeffs S; Jones I; Chen H; Seaman MS; Ferguson D; Almond N
    J Virol Methods; 2013 Dec; 194(1-2):89-93. PubMed ID: 23973741
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.
    Salomon A; Krachmarov C; Lai Z; Honnen W; Zingman BS; Sarlo J; Gorny MK; Zolla-Pazner S; Robinson JE; Pinter A
    Virology; 2014 Jan; 448():363-74. PubMed ID: 24314667
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins.
    Gao F; Scearce RM; Alam SM; Hora B; Xia S; Hohm JE; Parks RJ; Ogburn DF; Tomaras GD; Park E; Lomas WE; Maino VC; Fiscus SA; Cohen MS; Moody MA; Hahn BH; Korber BT; Liao HX; Haynes BF
    Virology; 2009 Nov; 394(1):91-8. PubMed ID: 19744690
    [TBL] [Abstract][Full Text] [Related]  

  • 79. HIV: Antibodies with a split personality.
    Plückthun A
    Nature; 2010 Sep; 467(7315):537-8. PubMed ID: 20882002
    [No Abstract]   [Full Text] [Related]  

  • 80. A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C.
    Kumar R; Andrabi R; Tiwari A; Prakash SS; Wig N; Dutta D; Sankhyan A; Khan L; Sinha S; Luthra K
    BMC Biotechnol; 2012 Nov; 12():87. PubMed ID: 23153214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.